Sanofi
SAN | PA
Overview
Corporate Details
- ISIN(s):
- FR0000120578 (+39 more)
- LEI:
- 549300E9PC51EN656011
- Country:
- France
- Address:
- 46 AVENUE DE LA GRANDE ARMEE, 75017 PARIS
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Sanofi S.A. is a French multinational healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but the firm also develops over-the-counter medication. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur).
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-23 07:00 |
Inside Information Statement
Communiqué de presse : Sarclisa recommandé pour approbation dans l’UE par le CH…
|
French | 232.8 KB | |
| 2025-06-23 07:00 |
Inside Information Statement
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transp…
|
English | 228.7 KB | |
| 2025-06-20 07:00 |
Inside Information Statement
Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médic…
|
French | 225.5 KB | |
| 2025-06-20 07:00 |
Inside Information Statement
Press Release: Dupixent approved in the US as the only targeted medicine to tre…
|
English | 212.2 KB | |
| 2025-06-17 13:40 |
Capital/Financing Update
Communiqué de presse : Sanofi place 1,5 milliard d’euros d’emprunts obligataires
|
French | 215.8 KB | |
| 2025-06-17 13:40 |
Capital/Financing Update
Press release: Sanofi successfully prices €1.5 billion bond issue
|
English | 179.4 KB | |
| 2025-06-16 22:40 |
Directors' Dealings
Sanofi : Déclaration des transactions sur actions propres
|
English | 1.4 MB | |
| 2025-06-16 22:40 |
Transaction in Own Shares
Sanofi: Disclosure of trading in own shares
|
English | 2.8 MB | |
| 2025-06-15 17:22 |
Earnings Release
Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la …
|
French | 218.3 KB | |
| 2025-06-15 17:22 |
Inside Information Statement
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab…
|
English | 213.9 KB | |
| 2025-06-09 23:09 |
Declaration of Voting Results & Voting Rights Announcements
Sanofi: Information concerning the total number of voting rights and shares - M…
|
English | 143.9 KB | |
| 2025-06-09 23:09 |
Declaration of Voting Results & Voting Rights Announcements
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mai 2…
|
French | 119.6 KB | |
| 2025-06-09 07:00 |
Regulatory News Service
Communiqué de presse : Sanofi accélère la livraison mondiale de Beyfortus pour …
|
French | 196.0 KB | |
| 2025-06-09 07:00 |
Regulatory News Service
Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healt…
|
English | 191.7 KB | |
| 2025-06-06 20:22 |
Transaction in Own Shares
Sanofi: Disclosure of trading in own shares
|
English | 111.5 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-02 | N/A | Other | Buy | 71,423 | N/A |
| 2024-04-26 | N/A | Other | Buy | 1,000 | 91,380.00 EUR |
| 2023-06-09 | N/A | Other | Buy | 9 | 856.04 EUR |
| 2023-05-02 | N/A | Other | Buy | 65,205 | 6,364,008.00 EUR |
| 2023-05-02 | N/A | Other | Buy | 500 | 48,835.00 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Camurus | Sweden | CAMX | |
|
Cannabotech Ltd. | Israel | CNTC | |
| Canzon Israel Ltd. | Israel | CNZN | ||
|
CATALYST MEDIA GROUP PLC | United Kingdom | CMX | |
|
Celon Pharma S.A. | Poland | CLN | |
|
Chemical Works of Gedeon Richter Plc | Hungary | RICHT | |
|
COSMO Pharmaceuticals N.V. | Netherlands (Kingdom of the) | COPN | |
|
DanCann Pharma A/S | Denmark | DANCAN | |
|
DARWIN AG | Germany | 7V0 | |
|
Dechra Pharmaceuticals PLC | United Kingdom | DPH |